Fibrocell Science, Inc. (FCSC) saw its loss widen to $2.30 million, or $0.05 a share for the quarter ended Sep. 30, 2016. In the previous year period, the company reported a loss of $1.52 million, or $0.07 a share.

Revenue during the quarter surged 172.15 percent to $0.22 million from $0.08 million in the previous year period.

Operating loss for the quarter was $5.02 million, compared with an operating loss of $6.82 million in the previous year period.

"Fibrocell is focused on advancing our innovative gene therapy candidates that use genetically-modified autologous fibroblast cells to target the underlying cause of debilitating skin and connective tissue diseases and have the potential to offer hope and relief to patients," said David Pernock, chairman and chief executive officer of Fibrocell. "We are pleased with the progress of the Phase I/II clinical trial of FCX-007 for the treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB), and continue to expect to dose the first subject in the Phase I portion of the trial at the end of 2016. Furthermore, development of FCX-013-our product candidate for the treatment of linear scleroderma-will be proceeding into a pre-clinical dose-ranging study this month, with a toxicology/biodistribution study to follow."